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Abstract 
Nonmyeloablative conditioning is less toxic and results in initial establishment of 
mixed hematopoietic T cell chimerism for up to half a year with prolonged presence of 
host T cell immunity. In this study, we examined whether this translates into differences 
in the risks and/or severity of cytomegalovirus (CMV) infection and disease. We 
analyzed data from 537 nonmyeloablative (NM-HCT) and contemporaneous 2489 
myeloablative hematopoietic cell transplant (M-HCT) recipients. In CMV seropositive 
recipients, no difference in the overall hazards of CMV infection at any level [adjusted 
hazard ratio (adj. HR) 0.9, 95% confidence interval (95%CI): 0.7-1.0, P=0.14] was noted; 
however, NM-HCT was associated with a lower risk of high-grade CMV infection (adj. 
HR 0.7, 95%CI: 0.5-0.9, P=0.02).  CMV disease rates were similar between the groups 
during the first 100 days after HCT but NM-HCT recipients had an increased risk of  late 
CMV disease (adj. HR 2.0, 95% CI 1.2-3.4).  The increased risk of late CMV disease 
after NM-HCT was pronounced during the earlier years of the study period but not 
detectable in more recent years. Contrary to earlier reports, survival following CMV 
disease was not reduced after NM-HCT when compared to M-HCT recipients. These 
results suggest that residual host cells after NM-HCT reduce progression to higher CMV 
viral load in NM-HCT recipients; however, this effect does not appear to protect against 
serious complications of CMV. Therefore, CMV prevention strategies in NM-HCT 
recipients should be similar to those used in M-HCT recipients.   
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Introduction 
 
Nonmyeloablative HCT (NM-HCT) is now widely used in patients with 
hematological and non-hematological malignancies who are ineligible for myeloablative 
HCT (M-HCT) due to advanced age or comorbidities (1-3). NM-HCT includes reduced or 
minimally intensive conditioning therapy before transplantation combined with more 
intensive immunosuppression after transplantation. The nonmyeloablative regimen used 
in Seattle consists of low-dose total body irradiation (TBI) 2 Gy with or without 
fludarabine followed by cyclosporine (CSP) or tacrolimus and mycophenolate mofetil 
(MMF) as post-grafting immunosuppression (3-9). This regimen causes minimal toxicity 
and results in initial establishment of mixed host/donor T cell chimerism for up to 
approximately 6 months. Thus, risk or severity of viral infections, such as 
cytomegalovirus (CMV) infection, may be reduced.  
     We initially reported that the time of CMV disease onset was delayed after HLA 
matched related NM-HCT, supporting the hypothesis that extended presence of host 
memory immune responses after NM-HCT might play a role in protection against early 
CMV infection (10-12). We also reported that the risk of CMV disease was similar after 
NM-HCT from HLA-matched-unrelated and related donors (13). Our study also 
suggested that CMV disease might be associated with a lower mortality in NM-HCT 
recipients (10). These studies were done early after the technique was introduced, which 
limited the power of statistical analyses due to small sample sizes.    
This report examines the incidence, risk, and outcome of CMV infection in a large 
cohort of recipients undergoing NM-HCT and compared the outcomes with those of 
contemporaneous M-HCT recipients. 
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Patients and Methods  
 
 This retrospective analysis was approved by the Institutional Review Board of the 
Fred Hutchinson Cancer Research Center (FHCRC; Seattle, WA). Informed consent 
was provided according to the Declaration of Helsinki. 
 
Patients 
        We compared outcomes in 537 consecutive patients who received NM-HCT 
between December 1997 and December 2005 at the FHCRC and 2489 patients who 
received M-HCT between January 1995 and December 2005 at the FHCRC (Table 1). 
Recipient and donor age, proportions of a prior transplant history, peripheral stem cell 
source, CMV high-risk patients and MMF use as a post-grafting immune suppressant 
were significantly higher in NM-HCT compared to M-HCT.  NM-HCT became more 
common in the later years and no T-depletion regimen was used in NM-HCT. 
The CMV risk was stratified into three groups: low (recipient negative and donor 
negative); intermediate (recipient negative and donor positive); and high (recipient 
positive and either donor negative or positive) based on recipient and donor CMV 
serostatus before HCT.   
 
Preparative conditioning regimens and sources for HCT 
Three hundred forty-eight (64.8%) NM-HCT recipients received fludarabine (30 
mg /m2/day for 3 consecutive days) and low-dose TBI (2 Gy, day 0), while 90 patients 
(16.8%) received low-dose TBI (2 Gy, day 0) alone. Patients in the M-HCT group 
received different types of conditioning. The most common regimens consisted of 
cyclophosphamide (60 mg/kg/day for 2 consecutive days) followed by TBI (12 - 13.2 Gy) 
or busulfan (4 mg/kg/day for 4 consecutive days) followed by cyclophosphamide (60 
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mg/kg/d for 2 consecutive days) in 805 (32.3%) and 779 (31.3%) patients, respectively 
(data not shown). The distribution of stem cell sources used in NM-HCT and M-HCT is 
shown in Table 1.  
 
Prophylaxis and diagnosis of graft-versus-host disease (GVHD)  
GVHD prophylaxis regimens are shown in Table 1. NM-HCT patients most 
commonly received CSP and MMF orally as immune suppressants post HCT. MMF was 
administered 15 mg/kg orally twice a day from day 0 to day 27 and discontinued for the 
HLA-match related NM-HCTs and MMF 15 mg/kg orally two or three times a day from 
day 0 to day 40 with a taper to day 96 for the unrelated NM-HCTs were given. For the 
single HLA-antigen and combined HLA-antigen and allele mismatched NM-HCTs, 15 
mg/kg MMF was given 3 times a day and was tapered at day 100 over 2 months (5-9). 
M-HCT patients most commonly received the combination of CSP and MTX. 
CSP was given at a dose of 1.5 mg/kg intravenously twice a day or 6.25 mg/kg orally 
twice a day. MTX was administered intravenously at a dose of 15 mg/m2 on day 1, and 
10 mg/m2 on day 3, 6, and 11. Diagnoses of acute GVHD or chronic GVHD were 
performed according to established criteria (14, 15).   
 
Infection surveillance and pre-emptive therapy against CMV 
CMV surveillance including polymerase chain reaction (PCR), pp65 antigenemia 
(AG) and blood culture was performed on a weekly basis until day 100. After day 100, 
surveillance and preemptive therapy were recommended for CMV intermediate and 
high-risk patients on a weekly or biweekly basis. Patients were monitored for the 
development of CMV infection and diseases until day 365. CMV pp65 AG was quantified 
as the average number of positive cells per 200,000 peripheral blood leukocytes and 
quantitative detection of CMV DNA in plasma by PCR was performed as described (16).  
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Ganciclovir (GCV) treatment was started when CMV AG/PCR became positive 
during the first 100 days after HCT. All patients with CMV AG at any level received GCV 
(5 mg/kg IV twice daily) for 7 to 14 days as induction therapy, followed by maintenance 
therapy with a half dose of GCV (5 mg/kg IV daily) or valganciclovir 900 mg once a day 
orally until negative surveillance testing was detected or day 100. After day 100, pre-
emptive therapy consisting of IV GCV or valganciclovir induction, followed by 
maintenance therapy, was recommended when CMV AG became positive or when PCR 
was greater than 1000 copies/mL. GCV was substituted with foscarnet in patients with 
neutropenia. 
           Between January 1995 and November 1998, no patients received acyclovir for 
varicella zoster virus (VZV) prevention; but herpes simplex virus (HSV) positive 
recipients were given acyclovir, 250 mg/m2 twice daily from day -7 until engraftment and 
resolution of mucositis. From November 1998 until May 2002, VZV seropositive HCT 
recipients received prophylaxis against VZV (acyclovir 250 mg/m2 intravenously followed 
by 800 mg orally or valacyclovir 500 mg orally, all drugs given twice per day for 1 year 
after transplantation (valacyclovir was preferred for patients who received more than 0.5 
mg/kg per day of steroids). HCT patients undergoing transplantation after May 2002 
received the same regimen until 1 year after transplantation. In patients who were still 
receiving inmmunosuppression at one year, acyclovir/valacyclovir prophylaxis was 
continued until 6 months after discontinuation of all immunosuppression (17).  
 
Definitions of CMV infection and disease 
CMV AG was diagnosed by blood pp65 antigen testing, CMV viremia by positive 
blood culture or shell vial centrifugation culture (10), and detection of CMV DNA by PCR 
(16). CMV disease was defined by established criteria (18).  
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Study endpoints  
In the present study, we evaluated the following 6 endpoints: 1) CMV infection 
(any CMV AG/DNA detection) by day 100; 2) high-grade CMV infection (CMV AG > 
10/200,000 peripheral blood leukocytes or PCR > 1000 copies/ml by day 100; 3) CMV 
viremia (culture)  by day 100; 4) CMV disease by day 100 and 1 year; 5) late CMV 
disease which occurred after day 100 after HCT; 6) survival after CMV disease. 
 
Statistical analysis 
Characteristics of NM-HCT and M-HCT patients were summarized using 
frequency counts and percentages for categorical variables and medians and ranges for 
continuous variables.  
The cumulative incidences of CMV infection, CMV high-grade infection, CMV 
disease and late CMV disease were compared between NM-HCT and M-HCT groups, 
with subsequent transplantation or death considered competing risks. Cumulative 
incidence curves for these endpoints also were stratified by CMV risk groups defined by 
donor and recipient seropositivity and by transplant year groupings between 1995 and 
2005. The probability of survival was estimated by the Kaplan-Meier method. Hazards 
were compared using the log-rank test. The median times to onset of CMV disease were 
compared by the Wilcoxon rank sum test.  
Univariate and multivariate Cox regression models were used to estimate hazard 
ratios and 95% confidence intervals (95% CI). Cox regression analyses for CMV 
infection, high-grade CMV infection, CMV viremia and CMV disease were performed in 
the CMV high-risk group. CMV viremia was analyzed in just a slightly smaller subset 
because CMV viremia was tested only through 12/2003. Covariates included 
recipient/donor age and sex, recipient/donor race, donor CMV serostatus, sex mismatch, 
HLA disparity, donor relationship, intensity of conditioning, stem cell source, HSV type I, 
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II serostatus, T cell depleted conditioning, transplantation year, disease risk, GVHD 
prophylaxis, acute GVHD and chronic GVHD. Additionally, CMV risk group and 
maximum values of CMV AG and PCR testing were evaluated as risk factors for CMV 
disease. 
Acute and chronic GVHD, CMV AG and PCR testing were analyzed as time-
dependent variables. Variables less than P=0.05 in the univariate models were 
candidates for the multivariate models. Nonmyeloablative vs. myeloablative conditioning 
was forced into multivariate models of all endpoints. 
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Results  
 
CMV Infection and Viremia 
Low and intermediate-risk group (D-/R-, D+/R-): The cumulative incidences of 
CMV infection by day 100 were similar between NM-HCT and M-HCT in CMV low and 
intermediate-risk groups. High-grade CMV infection was very rare, particularly in CMV 
low-risk groups and was not noted in any low-risk NM-HCT patient (Table 2)  
High-risk group (D-/R+, D+/R+): In CMV high-risk group (n=1571), there were 
trends towards lower CMV infection and high-grade CMV infection rates in NM-HCT 
(Table 2, Figure 1).  When high viral load was analyzed stratified by HLA-matched 
related vs. unrelated/HLA-mismatched related donor status in the CMV high-risk group, 
the lower incidence of high-grade CMV infection in NM-HCT was seen both in the HLA-
matched related and unrelated/HLA-mismatched related settings (Figure 2).  Unrelated 
and HLA-mismatched donor status was associated with a somewhat higher cumulative 
incidence of high-grade CMV infection at day 100 than HLA-matched related donor 
status (Figure 2). This effect was seen in both M-HCT and NM-HCT recipients. In the 
CMV high-risk group, other factors associated with increased risks of any CMV infection 
were recipient age and acute GVHD (III or IV).  Other factors associated with an 
increased risk of high-grade CMV infection were recipient race (other than Caucasian) 
and acute GVHD (Table 3).  
Among seropositive patients transplanted between 1995 and 2003 (n=1263), the 
incidence of CMV viremia (culture proven) by day 100 was significantly lower in NM-HCT 
compared with M-HCT (10% vs. 19%, P <0.001). However, in the multivariate model, the 
significance was not sustained. Other risk factors for CMV viremia were recipient race (other 
than Caucasian) (adj. HR 1.9, 95%CI: 1.2-3.0, P<0.01) and acute GVHD II to IV (adj. HR 
3.4, 95%CI: 2.2-5.2, P<0.0001). CMV viremia was less common in the later years of the 
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study period (2001-2003) compared to 1995-1997 (adj. HR 0.4, 95%CI: 0.6-0.6, P<0.0001) 
(data not shown). 
 
Time to CMV Negativity after Start of Preemptive Therapy 
As a surrogate marker for duration of anti-CMV treatment, we compared the 
duration from first positive to the first negative AG/PCR result between NM-HCT and M-
HCT and found no difference in all patients [median (range):7 (0-13) vs.7 (0-50) days, 
respectively, P=0.98] or in patients at high risk for CMV (seropositive recipients) [median 
(range):7 (0-13) vs.7 (0-50) days, respectively, P=0.97] 
 
 CMV Disease and Survival after CMV Disease 
Low and intermediate-risk group (D-/R-, D+/R-): Among CMV low and 
intermediate-risk groups, there was no significant statistical difference in the risk for CMV 
disease by day 100 and by 1 year between NM-HCT and M-HCT (Table 2).  
High-risk (D-/R+, D+/R+): In the CMV high-risk group, the cumulative incidence 
of CMV disease by day 100 (but not by 1 year) tended to be less frequent in NM-HCT 
compared with M-HCT (Table 2, 4).  A significant decline of CMV disease incidence was 
noted after 2001 compared to 1995-2000 (Figure 3a, b). The cumulative incidence for 
CMV disease in CMV high-risk NM-and M-HCT patients from 1995 to 2000 were 27% 
vs. 18% (P=0.25) compared to 12% vs. 11% (P=0.94) between 2001 and 2005 (Figure 
3a, b). A significant delay in the onset of CMV disease was observed in NM-HCT in the 
high-risk CMV group [median day of onset; 106.5 (6.0-1273.0) vs. 69.5 days (6.0-
1775.0) P=0.02]. Among NM-HCT, the cumulative incidences of CMV disease at 1 year 
between HLA-matched related and unrelated/HLA-mismatched related donors were very 
similar (15% vs. 14%, P=0.87). 
Other risk factors associated with CMV disease in multivariate analysis were donor 
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female sex, acute GVHD, chronic GVHD, HSV type I seropositivity, and positivity of CMV 
AG and/or PCR (Table 4). 
The probability of survival in CMV high-risk patients who developed CMV disease 
(n=226) was not significantly different between NM-HCT and M-HCT recipients (P=0.88) 
(Figure 4). 
 
Late CMV Disease  
      
Low and intermediate-risk group (D-/R-, D+/R-): No statistical significant 
differences in incidences were observed between MN-HCT and M-HCT. Late CMV 
disease was not observed in any CMV low-risk NM-HCT patient (Table 2).  
High-risk group (D-/R+, D+/R+): No statistically significant differences in late 
CMV disease incidences were detected between MN-HCT and M-HCT in CMV high-risk 
group (Table 2). 
  Among all the risk groups, NM-HCT was significantly associated with late CMV 
disease after adjustment for multiple covariates (adj. HR 2.0, P=0.01) (Table 4). 
However, this was mainly driven by a high incidence of late CMV disease during the 
earlier years of the study period (Figure 3c, d). Additional risk factors for late CMV 
disease were: HLA-mismatch or unrelated donor, acute GVHD (III or IV) or chronic 
GVHD before day 100, and maximum CMV AG >10/ PCR > 1000 copies/ml before day 
100.  Furthermore, late CMV disease was less common in more recent years (2001-
2005) compared to 1995-1997 (Table 4).  
 
Secondary invasive bacterial and fungal infection after CMV infection 
        We compared the incidences of secondary bacterial infection before day 100 and 
fungal infections before 1 year after HCT between NM-HCT and M-HCT. There was no 
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significant difference in risk of probable and definite invasive fungal infection between 
NM-HCT and M-HCT in all CMV risk groups (p=0.77), nor in high-CMV-risk group 
(p=0.83). 
     Secondary invasive bacterial infections were less common in NM-HCT (23% vs. 28%, 
Chi square p-value <0.0001). There was a significant difference in hazard of bacterial 
infection between NM-HCT and M-HCT adjusted for CMV risk group (HR=0.6, 95% 
CI=0.5-0.8, P<0.0001); when the analysis was restricted to the CMV high risk group 
(seropositive recipients), a similar effect was seen (HR=0.7, 95% CI=0.5-0.9, P<0.01). 
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Discussion  
 
 We comprehensively examined risks and outcomes of CMV infection and 
disease in a large cohort of uniformly treated patients that provided the necessary power 
to analyze CMV endpoints in NM-HCT recipients.  NM-HCT recipients had similar rates 
of CMV infection and disease compared to M-HCT, although a delayed timing of disease 
and lower maximum CMV viral loads were noted. Contrary to an earlier small study that 
showed a trend towards improved outcome of CMV disease in NM-HCT (10), the 
present study did not show evidence of such an effect.    
 In a previous study, we demonstrated that NM-HCT showed trends towards lower 
incidence of CMV infection pp65 antigenemia, CMV viremia, and CMV disease during 
the first 100 days after HCT. However, we did not show statistically significant differences 
in the incidence of these CMV events between NM-HCT and M-HCT, possibly due to the 
small sample size (10). In the present study, we were able to provide statistical evidence 
that the incidence of high CMV viral load in NM-HCT is lower compared with M-HCT. 
This effect was seen in both HLA-mismatched-related or unrelated and HLA-matched-
related HCT recipients (Figure 2). Similar to an earlier study, there was a trend towards a 
more profound reduction of high CMV load in HLA-matched related NM-HCT recipients 
than in HLA-mismatched related or unrelated NM-HCT recipients, but even with this 
large sample size, this did not reach statistical significance (Figure 2).  We speculate that 
the strong immunosuppressants and/or the high incidence and severity of GVHD in HLA-
mismatched related or unrelated HCT might somewhat diminish the protection from 
persisting host T cell immunity in NM-HCT.  We confirmed that the onset of CMV disease 
was delayed, which resulted in a trend towards less CMV disease before day 100 in NM-
HCT recipients (Table 2). Collectively, these data suggest that the residual CMV specific 
host memory cells had a limited or no effect on reactivation of CMV but contributed to 
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preventing progression to higher levels of viral load, at least early after less intensive 
conditioning. This is consistent with laboratory studies that showed a persistence of host 
memory T cells in HLA-matched related NM-HCT recipients (11, 12). However, after 
complete donor chimerism has been achieved in NM-HCT recipients, the benefits of 
protection against CMV infection seem to disappear.  Our previous studies of CMV 
immunity showed that, after day 100, there was no difference in CMV-specific T cell 
immunity between NM-HCT and M-HCT recipients (11, 12).  
        Somewhat surprisingly, more patients developed late CMV disease following NM-
HCT compared to M-HCT.  Further analysis suggested that the effect was driven by the 
earlier years of the study period (10) (Figure 3c). This was likely due to less virologic 
surveillance for late CMV infection and less use of late preemptive therapy, possibly due 
to the perception that infectious complications were less frequent and/or severe (10).  
Additionally, the prolonged MMF prophylaxis or treatment, particularly in the unrelated 
NM-HCT, possibly contributed to more frequent incidence of late CMV disease in NM-
HCT than in M-HCT.  In more recent years, there was no increased risk of late CMV 
disease in NM-HCT recipients (Figure 3d).  Also, the overall incidence of late CMV 
disease declined in both NM and M-HCT recipients, likely due to extended monitoring of 
CMV by PCR and increased use of preemptive anti-CMV treatment beyond day 100. 
Risk factors for late CMV disease seen in this study (Table 4) were consistent 
with earlier reports by our group and others (20, 21, 22).  
Although we were unable to separate the effect of GVHD on the risk of CMV 
endpoints in our previous studies (10, 13), in the current  study, both acute GVHD and 
chronic GVHD were statistically significant risk factors for early and late CMV disease in 
the current study. This was consistent with previous reports (21). 
The strengths of this study were the large sample size permitting multivariate 
modeling, well defined and homogenous transplant protocols, highly standardized 
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supportive care, CMV surveillance, and a comprehensive and standardized workup of 
BAL and biopsy specimens (including autopsy specimens). Limitations were the 
retrospective nature of the analysis and that co-medications could only be analyzed by 
protocol (as supposed to on a per-patient basis). Also, the data might not extend to 
different reduced-intensity protocols. Furthermore, in this study, the majority of the NM-
HCT patients received peripheral blood stem cells (Table 1). Although we could not 
detect a significant effect of the stem cell on CMV outcomes in the multivariate models, 
NM-HCT and peripheral stem cell use are tightly linked so we cannot conclusively rule 
out an interaction between the two modalities (19). 
In conclusion, this large study provided robust data on the risk of CMV infection 
and disease in recipients of NM-HCT.  The study confirmed and added statistical 
strength to some of the earlier findings, including the delayed onset of CMV disease and 
a lower risk of progression to higher viral loads during the first 100 days. Of note, the 
earlier reported trend towards an improved outcome of CMV disease after NM-HCT 
could not be confirmed in this study. In addition, the study showed that the survival rate 
after CMV disease was still very unfavorable and emphasizes the need for improved 
prevention and treatment strategies for CMV.  Maribavir, a novel antiviral agent (23) and 
immune enhancement strategies with CMV-specific T cells (24) or CMV vaccination (25) 
or preemptive strategies that combine virologic and immunologic monitoring may be 
options in this regard. 
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  Table1. Characteristics of the Study Cohort 
 M-HCT (n=2489 ) NM-HCT (n=537 )  
Variable Number (%) Number (%) p-value 
Median (range) age,yrs  
     Patient 39.8 (0.5-67.0) 54.2 (0.5-74.5) <0.0001
     Donor  38.2 (0.7-81.7) 42.5 (1.3-83.3) <0.0001
Gender  
     Male 1422 (57.1) 334 (62.2) 
     Female 1067 (42.9) 203 (38.6) 0.03
Donor Gender  
     Male 1399 (56.2) 284 (52.9) 
     Female 1087 (43.7) 253 (47.1) 0.26
Recipient Race  
     Caucasian 2015 (81.0) 470 (87.5) 
     Other/unknown 474 (19.0) 67 (12.5) <0.001
Donor Race  
     Caucasian 1457 (58.5) 269 (50.1) 
     Other/unknown 1032 (41.5) 268 (49.9) <0.001
Year of Transplantation  
     1995-1997 834 (33.5) 1 (0.2) 
     1998-2000 716 (28.8) 116 (21.6) 
     2001-2003 578 (23.2) 225 (41.9) 
     2004-2005 361 (14.5) 195 (36.3) <0.0001
Prior Transplant (auto and/or allo)  
     Yes 74 (3.0) 202 (37.6) 
     No 2415 (97.0) 335 (62.4) <0.0001
Source of stem cell  
     BM 1431 (57.5) 49 (9.1) 
     PBSC 1015 (40.8) 487 (90.7) 
     Cord 43 (1.7) 1 (0.2) <0.0001
HLA Matching  
     Matched related 1017 (42.0) 221 (44.0) 
     Mismatched related/Unrelated 1404 (56.4) 281 (52.3) 0.28
CMV seropositive  
     Yes 1260 (50.6) 311 (57.9) 
     No 1228 (49.3) 225 (41.9) <0.01
Donor CMV seropositive  
     Yes 984 (39.5) 230 (42.8) 
     No 1503 (60.4) 307 (57.2) 0.30
CMV Risk  
     Low 894 (35.9) 152 (28.3) 
     Intermediate 334 (13.4) 73 (13.6) 
     High 1260 (50.6) 311 (57.9) <0.01
Disease Diagnosis  
     AA 67 (2.7) 2 (0.4) 
     ALL 346 (13.9) 21 (3.9) 
     AML 702 (28.2) 143 (26.6) 
     CLL 18 (0.7) 40 (7.5) 
     CML 669 (26.9) 18 (3.4) 
     HL 14 (0.6) 46 (8.6) 
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     MDS 465 (18.7) 41 (7.6) 
     MM 38 (1.5) 83 (15.5) 
     NHL 106 (4.3) 98 (18.3) 
     Congenital disorders 19 (0.8) 16 (3.0) 
     Other 44 (1.8) 29 (5.4) <0.0001
T-cell Depletion Regimen   
     Yes 270 (10.9) 0 (0.0) 
     No 2219 (89.2) 537 (100.0) <0.0001
Acute GVHD Prophylaxis  
     Calcineurin inhibitor only 27 (1.1) 17 (3.2) 
     Calcineurin inhibitor +MMF 66 (2.7) 495 (92.2) 
     Calcineurin inhibitor +MTX 2294 (92.2) 5 (0.9) 
     Other 101 (4.1) 20 (3.7) <0.0001
AA indicates aplastic anemia, ALL: acute lymphocytic leukemia; AML: acute myeloid leukemia; 
CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia; HL: Hodgkin lymphoma; 
MDS: myelodysplastic syndrome; MM: multiple myeloma; NHL: non-Hodgkin lymphoma; CMV: 
cytomegalovirus; BM: bone marrow; PBSC: peripheral blood stem cell; T-cell depletion regimens 
are those containing antithymocyte globulin or anti-CD3 antibody, BC3; acute GVH: acute graft-
versus-host disease and MMF: mycophenolate mofetil and MTX: methotrexate.  P-values from 
chi-square test, Fisher’s exact test or Wilcoxon rank-sum test as appropriate. 
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Table 2.  The Incidences of CMV infection and disease  
 
 
Endpoints  Incidence in 
M-HCT 
Incidence in 
NM-HCT 
P value 
CMV infection by day 100    
 Low-risk  0.03 0.02 .64 
 Intermediate-risk 0.15 0.21 .27 
 High-risk 0.66 0.62 .08 
High-grade CMV infection by day 100    
 Low-risk  0.01 0.00 .33 
 Intermediate-risk 0.05 0.09 .20 
 High-risk 0.25 0.14 <.0001 
CMV disease by day 100    
 Low-risk  0.01 0.01 .52 
 Intermediate-risk 0.01 0.02 .68 
 High-risk 0.10 0.07 .11 
CMV disease by 1 year    
 Low-risk  0.01 0.01 .96 
 Intermediate-risk 0.03 0.03 .95 
 High-risk 0.15 0.15 .50 
Late CMV disease     
 Low-risk  0.01 0.00 .35 
 Intermediate-risk 0.02 0.04 .68 
 High-risk 0.09 0.11 .52 
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Table 3. Univariate and Multivarite Analyses of Risk Factors for CMV infection in CMV high-risk group 
 CMV infection*  CMV high-grade infection*
 Factors Univariate 
HR (95%CI) 
P adj. HR 
(95%CI) 
P  Univariate 
 HR (95%CI) 
P adj. HR 
 (95%CI) 
P 
NM-HCT 0.9 (0.7-1.0) .08 0.9 (0.7-1.0) .14  0.5 (0.4-0.7) <.0001 0.7 (0.5-0.9) .02 
Recipient age  < 41 yrs 1.3 (1.1-1.4) <.001 1.5 (1.3-1.7) <.0001  0.9 (0.8-1.1) .46 - - 
Recipient Race (other than 
Caucasian) 
1.2 (1.0-1.4) .01 1.1 (0.9-1.4) .23  1.2 (1.0-1.6) .08 1.4 (1.1-1.9) <.01 
Donor CMV positive 1.0 (0.9-1.1) .56 - -  0.7 (0.6-0.9) .002 0.7 (0.6-0.9) <.01 
Related Donor  0.8 (0.7-0.9) <.0001 0.9 (0.7-1.2) .46  0.7 (0.5-0.8) .0001 0.6 (0.4-1.0) .04 
HSV1 positive (recipient)  0.7 (0.5-0.8) <.001 0.6 (0.5-0.8) <.001  1.0 (0.7-1.6) .92 - - 
Acute GVHD (III or IV) 1.5 (1.3-1.8) <.0001 1.4 (1.2-1.6) <.0001  2.2 (1.8-2.8) <.0001 1.8 (1.4-2.3) <.0001 
Year of transplant           
   1995-1997 1.0  1.0   1.0  1.0  
   1998-2000 0.8 (0.7-1.0) .01 0.8 (0.7-1.0) .01  0.7 (0.5-0.9) .006 0.7 (0.5-0.9) <.01 
   2001-2003 0.8 (0.7-1.0) .02 0.9 (0.7-1.1) .20  0.5 (0.4-0.7) <.0001 0.6 (0.4-0.8) <.001 
   2004-2005 0.8 (0.7-1.0) .04 0.8 (0.6-1.0) .05  0.4 (0.3-0.5) <.0001 0.4 (0.3-0.6) <.0001 
adj. HR: adjusted hazard ratio; CI: confidence interval; NM-HCT: nonmyeloablative allogeneic hematopoietic stem cell transplantation; CMV: 
cytomegalovirus. HSV1: herpes simplex virus type1; GVHD: graft-versus-host disease. The factors which were statistically significant in either 
multivariate model of CMV infection or high-grade CMV infection, and NM-HCT are displayed.   
* Total sample size of CMV high-risk patients is 1571. 
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Table 4. Univariate and Multivariate Analyses of Risk Factors for CMV Disease in CMV high-risk group 
 CMV disease*  Late CMV disease* 
 Factors Univariate 
HR (95%CI) 
P adj. HR 
(95%CI) 
P  Univariate
HR (95%CI) 
P adj. HR 
 (95%CI) 
P 
NM-HCT 0.9 (0.7-1.3) .74 1.3 (0.9-1.9) .12  1.2 (0.7-1.8) .52 2.0 (1.2-3.4) .01 
Donor sex (female) 1.3 (1.0-1.6) .08 1.4 (1.1-1.7) .02  1.2 (0.8-1.8) .31 - - 
Unrelated/HLA-mismatched  1.4 (1.1-1.8) <.01 1.2 (0.7-2.1) .44  2.5 (1.7-3.9) <.0001 2.1 (1.4-3.3) <.01 
HSV1 positive 2.0 (1.0-3.9) .04 2.3 (1.2-4.5) .01  2.6 (0.8-8.5) .12 - - 
Acute GVHD (III or IV) 2.7 (2.1-3.6) <.0001 2.1 (1.6-2.7) <.0001  - - - - 
Chronic GVHD 2.6 (1.8-3.8) <.0001 2.1 (1.4-3.0) <.0001  - - - - 
Acute (III or IV) or Chronic  
GVHD 
- - - -  6.0 (2.6-13.6) <.0001 4.1 (1.8-9.5) <.01 
Year of transplant           
   1995-1997 1.0  1.0   1.0  1.0  
   1998-2000 1.2 (0.9-1.7) .24 1.3 (0.9-1.8) .14  0.7 (0.4-1.8) .14 0.7 (0.4-1.1) .12 
   2001-2003 0.7 (0.5-0.9) .02 0.8 (0.5-1.4) .44  0.5 (0.3-0.8) <.01 0.4 (0.2-0.8) <.01 
   2004-2005 0.6 (0.4-0.9) .02 0.8 (0.5-1.3) .31  0.6 (0.3-1.0) .05 0.5 (0.3-0.9) .03 
Max. CMV AG           
    0 1.0  1.0   -  -  
    >0-2/200,000   1.7 (1.1-2.5) .01 1.7 (1.1-2.5) .01  - - - - 
    >2-10/200,000   1.6 (1.0-2.6) .05 1.4 (0.9-2.3) .16  - - - - 
    >10/200,000   4.7 (3.3-6.8) <.0001 3.7 (2.5-5.4) <.0001  - - - - 
Max. CMV PCR  (copies/ml)          
    0 1.0  1.0   -  -  
    0-1000 2.3 (1.4-3.8) <.01 2.4 (1.4-4.1) <.01  - - - - 
    >1000 2.4 (1.2-4.6) .01 3.2 (1.6-6.5) <.01  - - - - 
Max. CMV AG>10 /PCR>1000  
before day 100 (copies/ml) 
- - - -  2.8 (1.9-4.1) <.0001 2.0 (1.4-3.0) <.01 
adj. HR: adjusted hazard ratio; CI: confidence interval; NM-HCT: nonmyeloablative allogeneic hematopoietic stem cell transplantation; CMV: 
cytomegalovirus. HSV1: herpes simplex virus type1; GVHD: graft-versus-host disease; AG: antigenemia; PCR: polymerase chain reaction.  
The factors which were statistically significant in either multivariate model of CMV disease or late CMV disease, and NM-HCT are displayed 
* Thel sample size of CMV high-risk patients at risk for CMV disease is 1571; the sample size of CMV high-risk patients who survived CMV-
disease-free to day 100 and were at risk for late CMV disease is 1109.
 
Figure Legend  
 
Figure 1. Cumulative incidences of any and high-grade CMV infections in CMV 
high-risk patients  
The probabilities of a) any CMV infection and b) high-grade CMV infection (CMV AG > 
10 cells per 200,000 PBL or CMV DNA > 1000 copies per mL of plasma) in CMV high-
risk patients are displayed. The dashed line indicates nonmyeloablative hematopoietic 
cell transplant (NM-HCT) and the solid line indicates myeloablative hematopoietic cell 
transplant (M-HCT). P values were calculated by the log-rank test.  
 
Figure 2. Cumulative incidences of CMV high-grade infection in CMV high-risk 
patients stratified by matched-related vs. unrelated/HLA-mismatched donor 
A) myeloablative HLA-matched related donor, B) myeloablative unrelated/ HLA-
mismatched related donor, C) nonmyeloablative HLA-matched related donor, D) 
nonmyeloablative unrelated/ HLA-mismatched related donor. 
 
Figure 3. Cumulative incidences of CMV disease in CMV high-risk patients and late 
CMV disease  
The probabilities of a) CMV disease from1995 to 2000, b) CMV disease from 2001 to 
2005 in CMV high-risk patients, c) late CMV disease from1995 to 2000, and d) late CMV 
disease from 2000 to 2005 are displayed. The probability curves for late CMV were 
generated from all CMV high risk patients who survived beyond day 100 without 
underlying disease relapse. The dashed line indicates nonmyeloablative hematopoietic 
cell transplant (NM-HCT) and the solid line indicates myeloablative hematopoietic cell 
transplant (M-HCT). P values were calculated by the log-rank test. 
 
Figure 4. Survival after CMV disease in CMV high-risk patients.  
The probability of survival after CMV disease in 226 high-risk patients who had CMV 
disease. The dashed line indicates nonmyeloablative hematopoietic cell transplant (NM-
HCT) and the solid line indicates myeloablative hematopoietic cell transplant (M-HCT). P 
values were calculated by the log-rank test. 
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